Viking Therapeutics Inc (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced on Wednesday that it has reported its financial results for year ended 31 December 2019.
The company reported research and development for 2019 at USD23.6m compared to USD19m in 2018.
The firm posted general and administrative expenses were at USD9.1m in 2019 compared to USD7.1m in 2018.
For the twelve months ended 31 December 2019, Viking reported a net loss of USD25.8m, or USD0.36 per share, compared to a net loss of USD22.1m, or USD0.38 per share, in the corresponding period in 2018.
The company stated that the decrease in net loss per share for the twelve months ended 31 December 2019 was primarily driven by the additional weighted average shares outstanding at 31 December 2019 versus those outstanding at 31 December 2018, given the public equity financings that occurred during 2018.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients